Glioblastoma Multiforme (GBM) remains one of the most daunting frontiers in modern oncology. Classified as a Grade IV brain cancer, it is characterized by its terrifying speed, its ability to weave into healthy brain tissue, and its stubborn resistance to the "gold standard" of treatment—a combination of surgical resection, radiation, and chemotherapy. For patients diagnosed with GBM, the prognosis is often measured in months rather than years; even with aggressive intervention, most survive only 12 to 18 months.
The tragedy of glioblastoma is not just in its initial ferocity, but in its inevitable return. When the tumor relapses, it does so with a vengeance—growing faster, spreading further, and ignoring the drugs that might have previously held it at bay. For decades, scientists have scoured the genetic code of these tumors to understand why they are so resilient. However, groundbreaking research from the Indian Institute of Technology Bombay (IIT Bombay), in collaboration with other premier Indian institutes, suggests we may have been looking for answers in the wrong place.
The secret to glioblastoma’s aggression may not lie solely in its DNA, but in the physical environment of the brain itself. A series of studies from Prof. Abhijit Majumder’s mechanobiology laboratory at IIT Bombay reveals that the "softness" of brain tissue acts as a master switch for cancer-promoting genes—a switch that remains invisible when cells are studied on traditional laboratory equipment.
Main Facts: The Mismatch Between Plastic and Pathology
For over a century, the cornerstone of cancer research has been the Petri dish—a rigid plastic or glass surface where cells are grown, fed, and tested with drugs. While convenient and standardized, these surfaces are millions of times stiffer than the human brain. The brain is one of the softest tissues in the human body, possessing a consistency often compared to soft jelly or silken tofu.
Prof. Majumder’s team, alongside Prof. Shilpee Dutt from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (now at JNU), hypothesized that this mechanical mismatch was fundamentally altering how cancer cells behave. Their findings, published across journals such as Matrix Biology and Macromolecular Bioscience, demonstrate that:
- Stiffness Masks Aggression: Recurrent glioblastoma cells only reveal their true, invasive nature when grown on materials that mimic the softness of the brain.
- Hidden Drug Targets: Specific proteins that drive cancer growth, such as PLEKHA7, are "switched off" on hard plastic but "switched on" in soft environments, meaning potential life-saving drugs are being missed in early testing.
- RNA as a Sensor: A specific type of RNA molecule, NEAT1, acts as a mechanical sensor, translating the physical "feel" of the brain into chemical signals that accelerate tumor growth.
- The 3D Imperative: The three-dimensional architecture of a tumor further amplifies these aggressive signals, suggesting that 2D models are insufficient for capturing the reality of the disease.
Chronology: From Clinical Observation to Molecular Discovery
The research journey began with a clinical paradox. Clinicians have long observed that relapsed glioblastoma is significantly more aggressive than the original "parent" tumor. To investigate this, Prof. Shilpee Dutt’s team recreated the relapse process in a laboratory setting.
The Relapse Simulation
The researchers took primary glioblastoma cells and subjected them to high-dose radiation, mimicking the treatment a patient receives. While 90% of the cells perished, a small fraction survived. These "survivor cells" were allowed to regrow, effectively creating a laboratory model of a recurrent tumor.
The Plastic Deception
When these survivor cells were implanted into mice, they behaved exactly as they do in humans: they were highly invasive and lethal. However, a strange thing happened when the researchers grew the parent cells and the recurrent cells on standard plastic culture dishes. On plastic, the two populations looked and acted identically. The aggressive "edge" of the recurrent cells had seemingly vanished.
The Hydrogel Breakthrough
Suspecting that the rigid plastic was suppressing the cells’ natural behavior, Prof. Majumder’s team developed polyacrylamide hydrogels—engineered "jelly" surfaces with a softness calibrated to match real brain tissue. When the recurrent cells were placed on these soft gels, their behavior transformed. They became elongated and highly mobile, spreading across the gel with a speed never seen on plastic. The "clinical relapse" had finally been captured in a dish.
Supporting Data: The Discovery of PLEKHA7 and NEAT1
The shift from plastic to soft gels did more than change how the cells looked; it changed their molecular "signature."
The Case of PLEKHA7
By comparing the gene expression of cells on soft gels versus hard plastic, the researchers identified a protein called PLEKHA7. In the soft environment, PLEKHA7 levels spiked in recurrent cells. When the team checked biopsies from human patients who had suffered glioblastoma relapses, they found the same high levels of PLEKHA7. Crucially, on plastic dishes, this protein was almost non-existent. When the researchers blocked PLEKHA7, the tumor’s ability to survive and spread was significantly crippled. This proved that a viable drug target had been "hidden" by the use of improper testing surfaces.
NEAT1: The Mechanosensitive Molecule
The research then moved deeper into the cell’s machinery. Dr. Arpita Ghosh, a lead researcher in the follow-up studies, focused on NEAT1, a "long non-coding RNA" (lncRNA). Unlike traditional RNA, which provides instructions for making proteins, NEAT1 regulates how other genes are expressed.
Collaborating with Prof. Mohit Kumar Jolly at the Indian Institute of Science (IISc), Bengaluru, the team found that NEAT1 levels were 300% to 400% higher in cells grown on brain-mimicking gels compared to plastic. By using "RNA interference" to silence NEAT1, the researchers were able to stop the cancer cells from shape-shifting and spreading. This marked the first time an lncRNA was identified as a sensor for physical tissue stiffness.
The 3D Advantage (Tumoroids)
The final layer of data came from moving from 2D surfaces to 3D "tumoroids"—miniature, ball-like clusters of cancer cells. The team found that NEAT1 levels were 3.5 times higher in 3D models than even on 2D soft gels. In these 3D environments, the tumors developed "jagged, protruding edges," a physical hallmark of a cancer preparing to invade the surrounding brain. When NEAT1 was suppressed, these edges became smooth and compact, effectively "caging" the cancer.
Official Responses: A Call to Reform Cancer Research
The leaders of this research are vocal about the implications for the pharmaceutical industry. The current failure rate for new cancer drugs is staggering—approximately 90% of drugs that look promising in the lab fail when they reach human clinical trials.
"We suspected that the problem lay in the experimental model itself," says Prof. Abhijit Majumder. "While the brain is one of the softest tissues in the body, cancer cells are routinely studied on rigid plastic surfaces. The rigid surface didn’t just dull the cells’ aggressive behavior, it erased the very distinction between parent and recurrent cells that defines clinical relapse."
Prof. Shilpee Dutt emphasized the danger of missing potential cures: "A real, functionally validated drug target [like PLEKHA7] would have simply been missed using the conventional culture method most labs still rely on. If someone has a cancer drug target, they should now include soft-gels and tumoroids as an initial experiment."
Dr. Arpita Ghosh noted the groundbreaking nature of the NEAT1 discovery: "While proteins that respond to physical forces have been widely studied, lncRNA molecules like NEAT1 had never been examined as potential sensors of physical cues. This was one of the most crucial results that told us NEAT1 can translate physical cues into changes in tumor behavior."
Implications: Changing the Blueprint of Oncology
The body of work produced by the IIT Bombay-led consortium suggests a paradigm shift is necessary in how the global scientific community approaches cancer.
1. Beyond Genetics
For years, the focus has been on "Precision Medicine"—matching drugs to specific genetic mutations. This research proves that "Mechanomedicine" is an equally vital piece of the puzzle. A cell with the same DNA can behave in two entirely different ways depending on whether it "feels" a hard or soft surface.
2. Reducing Clinical Trial Failure
The massive cost of failed drug trials (often in the billions of dollars) is partly due to the fact that drugs are tested on "deceived" cells. By integrating brain-mimicking hydrogels and 3D tumoroids into the early stages of drug discovery, pharmaceutical companies could filter out ineffective compounds much earlier and identify targets that are only present in physiological conditions.
3. A Universal Phenomenon?
While the primary focus was glioblastoma, the researchers found that NEAT1 and other related molecules (like MALAT1) also responded to 3D environments in breast and lung cancer cells. This suggests that the "physical environment" rule applies to many forms of solid tumors, not just those in the brain.
4. New Therapeutic Pathways
The discovery of NEAT1 and PLEKHA7 as mechanosensitive drivers of cancer opens the door for a new class of "mechanoblockers"—drugs designed to prevent cancer cells from sensing or responding to the stiffness of their environment.
In conclusion, the work of Prof. Majumder and his colleagues serves as a stark reminder that in science, the medium is often as important as the message. By finally listening to the "soft" whispers of the brain, researchers may have found the key to silencing the loudest and most aggressive cancer of all.
